Occult hepatitis B: prevalence and clinical significance. Role in liver pathology and in viral coinfections

Cover Image

Cite item

Full Text

Abstract

The review examines issues related to occult hepatitis B virus infection (OBI), which occurs at a late stage of chronic hepatitis B (CHB) after HBsAg clearance. In clinical practice, OBI is detected by the absence of HBsAg and the presence of antibodies to HBcAg in the blood serum and is often referred to as «past» or «resolved» hepatitis B. However, hepatitis B virus (HBV) DNA remains in liver cells, is poorly detected by routine diagnostic methods, and cannot be removed by existing therapies. Data on the prevalence of OBI vary, but it is found in all regions of the world, much more often in regions with a high prevalence of HBV. Data on the association of OBI with fibrosis, cirrhosis and hepatocellular carcinoma (HCC) have been obtained. It has been established that OBI is associated with an increased risk of HBV reactivation in patients with infections with other viruses, as well as in cancer patients whose treatment includes immunosuppressive therapy. HBV reactivation leads to severe consequences and, in the absence of treatment, death of patients. It can be concluded that to achieve the goal set by WHO for the eradication of viral hepatitis by 2030, it is necessary to solve the problem of OBI. In order to make this possible, it is essential to create new, more sensitive and informative diagnostic tests, effective methods of HBV DNA elimination, and to investigate the mechanisms of OBI development in more depth.

About the authors

Alla A. Kushch

N.F. Gamaleya National Research Centre for Epidemiology and Microbiology, Ministry of Health of the Russian Federation

Author for correspondence.
Email: vitallku@mail.ru
ORCID iD: 0000-0002-3396-5533

D.Sci. (Biol.), Prof., Senior Researcher at the Laboratory of Cell Engineering

Russian Federation, 123098, Moscow

References

  1. Ou T.Y., Huy L.D., Mayne J., Shih C.L., Mai Xuan H., Thi Hong Nguyen N., et al. Global mortality of chronic liver diseases attributable to Hepatitis B virus and Hepatitis C virus infections from 1990 to 2019 and projections to 2030. J. Infect. Public Health. 2024; 17(7): 102443. https://doi.org/10.1016/j.jiph.2024.04.027.
  2. Tsukuda S., Watashi K. Hepatitis B virus biology and life cycle. Antiviral Res. 2020; 182: 104925. https://doi.org/10.1016/j.antiviral.2020.104925
  3. Mouzannar K., Schauer A., Liang T.J. The post-transcriptional regulatory element of hepatitis B virus: from discovery to therapy. Viruses. 2024; 16(4): 528. https://doi.org/10.3390/v16040528
  4. Panasiuk Ya.V., Vlasenko N.V., Churilova N.S., Klushkina V.V., Dubodelov D.V., Kudryavtseva E.N., et al. Modern views on the role of X gene of the hepatitis B virus (Hepadnaviridae: Orthohepadnavirus: Hepatitis B virus) in the pathogenesis of the infection it causes. Voprosy virusologii. 2022; 67(1): 7–17. https://doi.org/10.36233/0507-4088-84 https://elibrary.ru/tvufhi (in Russian)
  5. Li D., Hamadalnil Y., Tu T. Hepatitis B viral protein HBx: Roles in viral replication and hepatocarcinogenesis. Viruses. 2024; 16(9): 1361. https://doi.org/10.3390/v16091361.
  6. Asami J., Park J.H., Nomura Y., Kobayashi C., Mifune J., Ishimoto N., et al. Structural basis of hepatitis B virus receptor binding. Nat. Struct. Mol. Biol. 2024; 31(3): 447–54. https://doi.org/10.1038/s41594-023-01191-5
  7. Iwamoto M., Saso W., Sugiyama R., Ishii K., Ohki M., Nagamori S., et al. Epidermal growth factor receptor is a host-entry cofactor triggering hepatitis B virus internalization. Proc. Natl Acad. Sci. USA. 2019; 116(17): 8487–92. https://doi.org/10.1073/pnas.1811064116
  8. Gómez-Moreno A., Ploss A. Mechanisms of hepatitis B virus cccDNA and minichromosome formation and HBV gene transcription. Viruses. 2024; 16(4): 609. https://doi.org/10.3390/v16040609
  9. Gopalakrishna H., Ghany M.G. Perspective on emerging therapies to achieve functional cure of chronic hepatitis B. Curr. Hepatol. Rep. 2024; 23(2): 241–52. https://doi.org/10.1007/s11901-024-00652-9
  10. Sinha P., Thio C.L., Balagopal A. Intracellular host restriction of hepatitis B virus replication. Viruses. 2024; 16(5): 764. https://doi.org/10.3390/v16050764
  11. Yu X., Gong Q., Yu D., Chen Y., Jing Y., Zoulim F., et al. Spatial transcriptomics reveals a low extent of transcriptionally active hepatitis B virus integration in patients with HBsAg loss. Gut. 2024; 73(5): 797–809. https://doi.org/10.1136/gutjnl-2023-330577
  12. Zoulim F., Chen P.J., Dandri M., Kennedy P.T., Seeger C. Hepatitis B virus DNA integration: Implications for diagnostics, therapy, and outcome. J. Hepatol. 2024; 81(6): 1087–99. https://doi.org/10.1016/j.jhep.2024.06.037
  13. Yeh S.H., Li C.L., Lin Y.Y., Ho M.C., Wang Y.C., Tseng S.T., et al. Hepatitis B virus DNA integration drives carcinogenesis and provides a new biomarker for HBV-related HCC. Cell. Mol. Gastroenterol. Hepatol. 2023; 15(4): 921–9. https://doi.org/10.1016/j.jcmgh.2023.01.001
  14. Gu Z., Jiang Q., Abulaiti A., Chen X., Li M., Gao N., et al. Hepatitis B virus enhancer 1 activates preS1 and preS2 promoters of integrated HBV DNA impairing HBsAg secretion. JHEP Rep. 2024; 6(9): 101144. https://doi.org/10.1016/j.jhepr.2024.101144
  15. Maiorella R., Rodriguez V.A. Hepatitis B vaccine refusal in the newborn period. Pediatr. Ann. 2021; 50(8): e343–7. https://doi.org/10.3928/19382359-20210712-01
  16. Rajbhandari R., Chung R.T. Treatment of hepatitis B: A concise review. Clin. Transl. Gastroenterol. 2016; 7(9): e190. https://doi.org/10.1038/ctg.2016.46
  17. Michalak T.I., Pasquinelli C., Guilhot S., Chisari F.V. Hepatitis B virus persistence after recovery from acute viral hepatitis. J. Clin. Invest. 1994; 93(1): 230–9. https://doi.org/10.1172/JCI116950
  18. Hirode G., Choi H.S.J., Chen C.H., Su T.H., Seto W.K., Van Hees S., et al. Off-therapy response after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B: An international, multicenter, multiethnic cohort (RETRACT-B Study). Gastroenterology. 2022; 162(3): 757–71.e4. https://doi.org/10.1053/j.gastro.2021.11.002.
  19. Di Dato F., Iorio R. Expanding indications for chronic hepatitis B treatment: Is it really desirable to treat everyone? World J. Gastroenterol. 2024; 30(17): 2294–7. https://doi.org/10.3748/wjg.v30.i17.2294
  20. Gerlich W.H., Bremer C., Saniewski M., Schüttler C.G., Wend U.C., Willems W.R., et al. Occult hepatitis B virus infection: detection and significance. Dig. Dis. 2010; 28(1): 116–25. https://doi.org/10.1159/000282074
  21. Kleinman S.H., Busch M.P. Assessing the impact of HBV NAT on window period reduction and residual risk. J. Clin. Virol. 2006; 36(Suppl. 1): S23–9. https://doi.org/10.1016/s1386-6532(06)80005-3
  22. Golubeva I.F., Shal’nova E.E., Bochkova G.B. Infection risks and ensuring the safety of donated blood and its components. Laboratornaya diagnostika infektsionnykh zabolevaniy. 2019; (1): 6–21. (in Russian)
  23. Heim K., Sagar, Sogukpinar Ö., Llewellyn-Lacey S., Price D.A., Emmerich F., et al. Attenuated effector T cells are linked to control of chronic HBV infection. Nat. Immunol. 2024; 25(9): 1650–62. https://doi.org/10.1038/s41590-024-01928-4
  24. European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J. Hepatol. 2017; 67(2): 370–98. https://doi.org/10.1016/j.jhep.2017.03.021
  25. Budzinska M.A., Shackel N.A., Urban S., Tu T. Cellular genomic sites of hepatitis B virus DNA integration. Genes (Basel). 2018; 9(7): 365. https://doi.org/10.3390/genes9070365
  26. Raimondo G., Locarnini S., Pollicino T., Levrero M., Zoulim F., Lok A.S., et al. Update of the statements on biology and clinical impact of occult hepatitis B virus infection. J. Hepatol. 2019; 71(2): 397–408. https://doi.org/10.1016/j.jhep.2019.03.034
  27. Wang C., Xue R., Wang X., Xiao L., Xian J. High-sensitivity HBV DNA test for the diagnosis of occult HBV infection: commonly used but not reliable. Front. Cell. Infect. Microbiol. 2023; 13: 1186877. https://doi.org/10.3389/fcimb.2023.1186877
  28. Fang Z.L., Zhuang H., Wang X.Y., Ge X.M., Harrison T.J. Hepatitis B virus genotypes, phylogeny and occult infection in a region with a high incidence of hepatocellular carcinoma in China. World J. Gastroenterol. 2004; 10(22): 3264–8. https://doi.org/10.3748/wjg.v10.i22.3264
  29. Mo Y., Jin F., Li D., Zou W., Zhong J., Tong Z., et al. Prevalence and molecular characteristics of occult hepatitis B virus infection among blood donors in Huzhou City, eastern China. Gene. 2024; 927: 148718. https://doi.org/10.1016/j.gene.2024.148718
  30. Pisaturo M., Onorato L., Russo A., Chiodini P., Coppola N. An estimation of the prevalence of occult HBV infection in Western Europe and in Northern America: A meta-analysis. J. Viral Hepat. 2020; 27(4): 415–27. https://doi.org/10.1111/jvh.13248
  31. Ji D.Z., Pang X.Y., Shen D.T., Liu S.N., Goyal H., Xu H.G. Global prevalence of occult hepatitis B: A systematic review and meta-analysis. J. Viral Hepat. 2022; 29(5): 317–29. https://doi.org/10.1111/jvh.13660
  32. Fu M.X., Faddy H.M., Candotti D., Groves J., Saa P., Styles C., et al. International review of blood donation screening for anti-HBc and occult hepatitis B virus infection. Transfusion. 2024; 64(11): 2144–56. https://doi.org/10.1111/trf.18018
  33. Serikova E.N., Semenov A.V., Ostankova Yu.V., Totolian A.A. A method for detecting hepatitis B virus in blood plasma at low viral load using real-time PCR. Klinicheskaya laboratornaya diagnostika. 2021; 65(1): 59–64. https://doi.org/10.18821/0869-2084-2021-66-1-59-64 https://elibrary.ru/fagbfm (in Russian)
  34. Tung T.T., Schmid J., Nghia V.X., Cao L.C., Linh L.T.K, Rungsung I., et al. Low risk of occult hepatitis B infection among Vietnamese blood donors. Pathogens. 2022; 11(12): 1524. https://doi.org/10.3390/pathogens11121524
  35. Ndow G., Cessay A., Cohen D., Shimakawa Y., Gore M.L., Tamba S., et al. Prevalence and clinical significance of occult hepatitis B infection in the Gambia, West Africa. J. Infect. Dis. 2022; 226(5): 862–70. https://doi.org/10.1093/infdis/jiab327
  36. Mbencho M.N., Hafza N., Cao L.C., Mingo V.N., Achidi E.A., Ghogomu S.M., et al. Incidence of Occult Hepatitis B Infection (OBI) and hepatitis B genotype characterization among blood donors in Cameroon. PLoS One. 2024; 19(10): e0312126. https://doi.org/10.1371/journal.pone.0312126.
  37. Simpore A., Bazie B.V.E.J.T., Yooda P.A., Zoure A.A., Sawadogo S., Sawadogo A.G., et al. Seroprevalence of viral hepatitis B and occult hepatitis B among blood donors in Africa: a systematic review and meta-analysis. Rev. Med. Virol. 2024; 34(6): e70006. https://doi.org/10.1002/rmv.70006
  38. Semenenko T.A., Yarosh L.V., Bazhenov A.I., Nikitina G.Yu., Kleimenov D.A., Elgort D.A., et al. Epidemiological assessment of the prevalence of “occult” forms and HBsAg mutants of hepatitis B virus in hematological patients. Epidemiologiya i vaktsinoprofilaktika. 2012; (6): 9–14. (in Russian)
  39. Ostankova Yu.V., Serikova E.N., Shirshova N.Yu., Kuseviczkaya M.B., Gorskaya O.A., Basina V.V., et al. Prevalence of latent form of chronic hepatitis B among blood donors in St. Petersburg. Infektsiya i immunitet. 2023; 13(6): 1129–40. https://doi.org/10.15789/2220-7619-POO-14480 https://elibrary.ru/xhpybw (in Russian)
  40. Ganina A.A., Kyuregyan K.K., Isaeva O.V., Dmitriev P.N., Mardanly S.G., Michailov M.I. The frequency of detection of “occult” hepatitis B among people with drug addiction and blood donors. Narkologiya. 2008; 7(9): 70–4. https://elibrary.ru/kaybtf (in Russian).
  41. Xia R., Peng J., He J., Jiang P., Yuan C., Liu X., et al. The serious challenge of occult hepatitis B virus infection-related hepatocellular carcinoma in China. Front. Microbiol. 2022; 13: 840825. https://doi.org/10.3389/fmicb.2022.840825
  42. Im Y.R., Jagdish R., Leith D., Kim J.U., Yoshida K., Majid A., et al. Prevalence of occult hepatitis B virus infection in adults: a systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 2022; 7(10): 932–42. https://doi.org/10.1016/S2468-1253(22)00201-1.
  43. Bucio-Ortiz L., Enriquez-Navarro K., Maldonado-Rodríguez A., Torres-Flores J.M., Cevallos A.M., Salcedo M., et al. Occult hepatitis B virus infection in hepatic diseases and its significance for the WHO’s elimination plan of viral hepatitis. Pathogens. 2024; 13(8): 662. https://doi.org/10.3390/pathogens13080662
  44. Takuissu G.R., Kenmoe S., Amougou Atsama M., Atenguena Okobalemba E., Mbaga D.S., Ebogo-Belobo J.T., et al. Global epidemiology of occult hepatitis B virus infections in blood donors, a systematic review and meta-analysis. PLoS One. 2022; 17(8): e0272920. https://doi.org/10.1371/journal.pone.0272920
  45. Candotti D., Boizeau L., Laperche S. Occult hepatitis B infection and transfusion-transmission risk. Transfus. Clin. Biol. 2017; 24(3): 189–95. https://doi.org/10.1016/j.tracli.2017.06.014
  46. Pisaturo M., Onorato L., Russo A., Coppola N. Prevalence of occult HBV infection in Western countries. J. Med. Virol. 2020; 92(12): 2917–29. https://doi.org/10.1002/jmv.25867
  47. Elbahrawy A., Alaboudy A., El Moghazy W., Elwassief A., Alashker A., Abdallah A.M. Occult hepatitis B virus infection in Egypt. World J. Hepatol. 2015; 7(12): 1671–8. https://doi.org/10.4254/wjh.v7.i12.1671
  48. Azzam A., Khaled H., El-Kayal E.S., Gad F.A., Omar S. Prevalence of occult hepatitis B virus infection in Egypt: a systematic review with meta-analysis. J. Egypt. Public Health Assoc. 2023; 98(1): 13. https://doi.org/10.1186/s42506-023-00138-4
  49. Kajogoo V.D., Swai S.S., Gurung S. Prevalence of occult hepatitis B among HIV-positive individuals in Africa: A systematic review and meta-analysis. SAGE Open Med. 2022; 10: 20503121211072748. https://doi.org/10.1177/20503121211072748
  50. Enriquez-Navarro K., Maldonado-Rodriguez A., Rojas-Montes O., Torres-Ibarra R., Bucio-Ortiz L., De la Cruz M.A., et al. Identification of mutations in the S gene of hepatitis B virus in HIV positive Mexican patients with occult hepatitis B virus infection. Ann. Hepatol. 2020; 19(5): 507–15. https://doi.org/10.1016/j.aohep.2020.06.002
  51. García-Montalvo B.M., Ventura-Zapata L.P. Molecular and serological characterization of occult hepatitis B infection in blood donors from Mexico. Ann. Hepatol. 2011; 10(2): 133–41.
  52. Morozov I.A., Il’chenko L.Yu., Gromova N.I., Fyodorov I.G., Gordeychuk I.V., Knyazhentseva A.K., et al. Problems of latent infection caused by the hepatitis B virus. Rossiyskiy zhurnal gastroenterologii, gepatologii, koloproktologii. 2012; 22(4): 58–65. https://elibrary.ru/piwdpl (in Russian)
  53. Delghandi S., Raoufinia R., Shahtahmasbi S., Meshkat Z., Gouklani H., Gholoobi A. An overview of occult hepatitis B infection (OBI) with emphasis on HBV vaccination. Heliyon. 2024; 10(17): e37097. https://doi.org/10.1016/j.heliyon.2024.e37097
  54. Yip T.C., Wong G.L., Wong V.W., Tse Y.K., Lui G.C., Lam K.L., et al. Durability of hepatitis B surface antigen seroclearance in untreated and nucleos(t)ide analogue-treated patients. J. Hepatol. 2017; 68(1): 63–72. https://doi.org/10.1016/j.jhep.2017.09.018
  55. Liu W.J., Wu W.J., Lin C.L., Liu C.J., Huang Y.W., Hu J.T., et al. Impact of age at HBsAg seroclearance on hepatic outcomes and life expectancy in men with chronic HBV infection based on multi-state modeling of the natural history. J. Gastroenterol. 2025; 60(1): 107–17. https://doi.org/10.1007/s00535-024-02162-3
  56. Leowattana W., Leowattana P., Leowattana T. Quantitative hepatitis B core antibody and quantitative hepatitis B surface antigen: Novel viral biomarkers for chronic hepatitis B management. World J. Hepatol. 2024; 16(4): 550–65. https://doi.org/10.4254/wjh.v16.i4.550
  57. El Jamaly H., Eslick G.D., Weltman M. Meta-analysis: hepatitis B reactivation in patients receiving biological therapy. Aliment. Pharmacol. Ther. 2022; 56(7): 1104–8. https://doi.org/10.1111/apt.17155
  58. Morrone A., Fiorilli V., Cinti L., Roberto P., Ferri A.L., Visentini M., et al. Surface antigen serocleared hepatitis B virus infection increases the risk of mixed cryoglobulinemia vasculitis in male patients with chronic hepatitis C. Front. Immunol. 2024; 15: 1411146. https://doi.org/10.3389/fimmu.2024.1411146
  59. Saravanan S., Shankar E.M., Vignesh R., Ganesh P.S., Sankar S., Velu V., et al. Occult hepatitis B virus infection and current perspectives on global WHO 2030 eradication. J. Viral Hepat. 2024; 31(7): 423–31. https://doi.org/10.1111/jvh.13928
  60. Peng J., Yao X., Yuan C., Liu X., Xia R., He J., et al. The investigation of hepatitis B vaccine immune responses in occult hepatitis B virus-infected patients. Front Immunol. 2022; 13: 903685. https://doi.org/10.3389/fimmu.2022.903685
  61. Tang X., Yang L., Zhang P., Wang C., Luo S., Liu B., et al. Occult hepatitis B virus infection and liver fibrosis in Chinese patients. J. Infect. Dis. 2023; 228(10): 1375–84. https://doi.org/10.1093/infdis/jiad140
  62. Yurlov K.I., Masalova O.V., Kisteneva L.B., Khlopova I.N., Samokhvalov E.I., Malinovskaya V.V. et al. Human herpesviruses increase the severity of hepatitis. Biology (Basel). 2021; 10(6): 483. https://doi.org/10.3390/biology10060483
  63. Berasain C., Betés M., Panizo A., Ruiz J., Herrero J.I., Civeira M.P., et al. Pathological and virological findings in patients with persistent hypertransaminasaemia of unknown aetiology. Gut. 2000; 47(3): 429–35. https://doi.org/10.1136/gut.47.3.429
  64. Kaviani M.J., Behbahani B., Mosallaii M.J., Sari-Aslani F., Taghavi S.A. Occult hepatitis B virus infection and cryptogenic chronic hepatitis in an area with intermediate prevalence of HBV infection. World J. Gastroenterol. 2006; 12(31): 5048–50. https://doi.org/10.3748/wjg.v12.i31.5048
  65. Anvari F.A., Alavian S.M., Norouzi M., Mahabadi M., Jazayeri S.M. Prevalence and molecular analysis of occult hepatitis B virus infection isolated in a sample of cryptogenic cirrhosis patients in Iran. Oman Med. J. 2014; 29(2): 92–6. https://doi.org/10.5001/omj.2014.23
  66. Hashemi S.J., Hajiani E., Masjedizadeh A., Makvandi M., Shayesteh A.A., Alavinejad S.P., et al. Occult hepatitis B infection in patients with cryptogenic liver cirrhosis in southwest of Iran. Jundishapur J. Microbiol. 2015; 8(3): e16873. https://doi.org/10.5812/jjm.16873
  67. Agarwal N., Naik S., Aggarwal R., Singh H., Somani S.K., Kini D., et al. Occult hepatitis B virus infection as a cause of cirrhosis of liver in a region with intermediate endemicity. Indian J. Gastroenterol. 2003; 22(4): 127–31.
  68. Ferrari T.C., Xavier M.A., Vidigal P.V., Amaral N.S., Diniz P.A., Resende A.P., et al. Occult hepatitis B virus infection in liver transplant patients in a Brazilian referral center. Braz. J. Med. Biol. Res. 2014; 47(11): 990–4. https://doi.org/10.1590/1414-431X20143782
  69. Faria A.C., Correa B.H.M., Faria L.C., Vidigal P.V.T., Xavier M.A.P., Ferrari T.C.A. Occult hepatitis B virus infection in patients with chronic liver disease of different etiology in a Brazilian referral center: comparison of two different hepatitis B virus deoxyribonucleic acid amplification protocols: a cross-sectional study. Sao Paulo Med. J. 2022; 141(3): e2022147. https://doi.org/10.1590/1516-3180.2022.0147.R1.12072022
  70. Daher D., Seif El Dahan K., Cano A., Gonzales M., Ransom C., Jaurez E., et al. Hepatocellular carcinoma surveillance patterns and outcomes in patients with cirrhosis. Clin. Gastroenterol. Hepatol. 2024; 22(2): 295–304.e2. https://doi.org/10.1016/j.cgh.2023.08.003
  71. Kim G.A., Lee H.C., Kim M.J., Ha Y., Park E.J., An J., et al. Incidence of hepatocellular carcinoma after HBsAg seroclearance in chronic hepatitis B patients: a need for surveillance. J. Hepatol. 2015; 62(5): 1092–9. https://doi.org/10.1016/j.jhep.2014.11.031
  72. Yip T.C., Wong G.L., Chan H.L., Tse Y.K., Lam K.L., Lui G.C., et al. HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues. J. Hepatol. 2019; 70(3): 361–70. https://doi.org/10.1016/j.jhep.2018.10.014
  73. Yang H., Bae S.H., Nam H., Lee H.L., Lee S.W., Yoo S.H., et al. A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance. J. Hepatol. 2022; 77(3): 632–41. https://doi.org/10.1016/j.jhep.2022.03.032
  74. Yip T.C., Wong V.W., Lai M.S., Lai J.C., Hui V.W., Liang L.Y., et al. Risk of hepatic decompensation but not hepatocellular carcinoma decreases over time in patients with hepatitis B surface antigen loss. J. Hepatol. 2023; 78(3): 524–33. https://doi.org/10.1016/j.jhep.2022.11.020
  75. Varghese N., Majeed A., Nyalakonda S., Boortalary T., Halegoua-DeMarzio D., Hann H.W. Review of related factors for persistent risk of hepatitis B virus-associated hepatocellular carcinoma. Cancers (Basel). 2024; 16(4): 777. https://doi.org/10.3390/cancers16040777
  76. Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2021; 71(3): 209–49. https://doi.org/10.3322/caac.21660
  77. Zhou M., Wang H., Zeng X., Yin P., Zhu J., Chen W., et al. Mortality, morbidity, and risk factors in China and its provinces, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2019; 394(10204): 1145–58. https://doi.org/10.1016/S0140-6736(19)30427-1
  78. Péneau C., Imbeaud S., La Bella T., Hirsch T.Z., Caruso S., Calderaro J., et al. Hepatitis B virus integrations promote local and distant oncogenic driver alterations in hepatocellular carcinoma. Gut. 2022; 71(3): 616–26. https://doi.org/10.1136/gutjnl-2020-323153
  79. Dias J.D., Sarica N., Cournac A., Koszul R., Neuveut C. Crosstalk between hepatitis B virus and the 3d genome structure. Viruses. 2022; 14(2): 445. https://doi.org/10.3390/v14020445
  80. Zhang M., Chen H., Liu H., Tang H. The impact of integrated hepatitis B virus DNA on oncogenesis and antiviral therapy. Biomark. Res. 2024; 12(1): 84. https://doi.org/10.1186/s40364-024-00611-y
  81. Huo T.I., Wu J.C., Lee P.C., Chau G.Y., Lui W.Y., Tsay S.H., et al. Sero-clearance of hepatitis B surface antigen in chronic carriers does not necessarily imply a good prognosis. Hepatology. 1998; 28(1): 231–6. https://doi.org/10.1002/hep.510280130
  82. Yuen M.F., Wong D.K., Fung J., Ip P., But D., Hung I., et al. HBsAg seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology. 2008; 135(4): 1192–9. https://doi.org/10.1053/j.gastro.2008.07.008
  83. Yip T.C., Chan H.L., Wong V.W., Tse Y.K., Lam K.L., Wong G.L. Impact of age and gender on risk of hepatocellular carcinoma after hepatitis B surface antigen seroclearance. J. Hepatol. 2017; 67(5): 902–8. https://doi.org/10.1016/j.jhep.2017.06.019
  84. Ji M., Hu K. Recent advances in the study of hepatitis B virus covalently closed circular DNA. Virol. Sin. 2017; 32(6): 454–64. https://doi.org/10.1007/s12250-017-4009-4
  85. Kaur S.P., Talat A., Karimi-Sari H., Grees A., Chen H.W., Lau D.T.Y., et al. Hepatocellular carcinoma in hepatitis B virus-infected patients and the role of hepatitis B surface antigen (HBsAg). J Clin Med. 2022; 11(4): 1126. https://doi.org/10.3390/jcm11041126.
  86. Ghany M.G., Buti M., Lampertico P., Lee H.M.; 2022 AASLD-EASL HBV-HDV Treatment Endpoints Conference Faculty. Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: Report from the 2022 AASLD-EASL HBV-HDV Treatment Endpoints Conference. J. Hepatol. 2023; 79(5): 1254–69. https://doi.org/10.1016/j.jhep.2023.06.002
  87. Gounder P.P., Bulkow L.R., Snowball M., Negus S., Spradling P.R., Simons B.C., et al. Nested case-control study: hepatocellular carcinoma risk after hepatitis B surface antigen seroclearance. Aliment. Pharmacol. Ther. 2016; 43(11): 1197–207. https://doi.org/10.1111/apt.13621
  88. Kuang X.J., Jia R.R., Huo R.R., Yu J.J., Wang J.J., Xiang B.D., et al. Systematic review of risk factors of hepatocellular carcinoma after hepatitis B surface antigen seroclearance. J. Viral Hepat. 2018; 25(9): 1026–37. https://doi.org/10.1111/jvh.12905
  89. Mak L.Y., Wong D.K., Pollicino T., Raimondo G., Hollinger F.B., Yuen M.F. Occult hepatitis B infection and hepatocellular carcinoma: Epidemiology, virology, hepatocarcinogenesis and clinical significance. J. Hepatol. 2020; 73(4): 952–64. https://doi.org/10.1016/j.jhep.2020.05.042
  90. Wong D.K., Cheng S.C.Y., Mak L.L., To E.W., Lo R.C., Cheung T.T., et al. Among patients with undetectable hepatitis B surface antigen and hepatocellular carcinoma, a high proportion has integration of HBV DNA into hepatocyte DNA and no cirrhosis. Clin. Gastroenterol. Hepatol. 2020; 18(2): 449–56. https://doi.org/10.1016/j.cgh.2019.06.029
  91. Huang Y., Li W., Hu H.T., Ruan S.M., Xian M.F., Xie X.Y., et al. Contrast-enhanced US diagnostic algorithm of hepatocellular carcinoma in patients with occult hepatitis B. Abdom. Radiol. (NY). 2022; 47(2): 608–17. https://doi.org/10.1007/s00261-021-03343-x
  92. Wong D.K., Huang F.Y., Lai C.L., Poon R.T., Seto W.K., Fung J., et al. Occult hepatitis B infection and HBV replicative activity in patients with cryptogenic cause of hepatocellular carcinoma. Hepatology. 2011; 54(3): 829–36. https://doi.org/10.1002/hep.24551
  93. Morozov S., Batskikh S. Commentary: Hepatitis B virus infection: an insight into the clinical connection and molecular interaction between hepatitis B virus and host extrahepatic cancer risk. Front Immunol. 2023; 14: 1200405. https://doi.org/10.3389/fimmu.2023.1200405
  94. Batskikh S., Morozov S., Dorofeev A., Borunova Z., Kostyushev D., Brezgin S., et al. Previous hepatitis B viral infection-an underestimated cause of pancreatic cancer. World J. Gastroenterol. 2022; 28(33): 4812–22. https://doi.org/10.3748/wjg.v28.i33.4812
  95. Rosenberg M., Poluch M., Thomas C., Sindaco P., Khoo A., Porcu P. Hepatitis B virus and B-cell lymphoma: evidence, unmet need, clinical impact, and opportunities. Front. Oncol. 2023; 13: 1275800. https://doi.org/10.3389/fonc.2023.1275800
  96. Dunleavy K. Double-hit lymphoma: optimizing therapy. Hematology Am. Soc. Hematol. Educ. Program. 2021; 2021(1): 157–63. https://doi.org/10.1182/hematology.2021000247
  97. Barraclough A., Hawkes E., Sehn L.H., Smith S.M. Diffuse large B-cell lymphoma. Hematol. Oncol. 2024; 42(6): e3202. https://doi.org/10.1002/hon.3202
  98. Li M., Gan Y., Fan C., Yuan H., Zhang X., Shen Y., et al. Hepatitis B virus and risk of non-Hodgkin lymphoma: an updated meta-analysis of 58 studies. J. Viral. Hepat. 2018; 25(8): 894–903. https://doi.org/10.1111/jvh.12892
  99. Spradling P.R., Xing J., Zhong Y., Rupp L.B., Moorman A.C., Lu M., et al. Incidence of malignancies among patients with chronic hepatitis B in US Health Care Organizations, 2006–2018. J. Infect. Dis. 2022; 226(5): 896–900. https://doi.org/10.1093/infdis/jiac011
  100. Bersoff-Matcha S.J., Cao K., Jason M., Ajao A., Jones S.C., Meyer T., et al. Hepatitis B virus reactivation associated with direct-acting antiviral therapy for chronic hepatitis C virus: a review of cases reported to the U.S. Food and Drug Administration Adverse Event Reporting System. Ann. Intern. Med. 2017; 166(11): 792–8. Doi: https://doi.org/10.7326/m17-0377
  101. Pisaturo M., Macera M., Alessio L., Calò F., Coppola N. Hepatitis B virus (HBV) reactivation following pharmacological eradication of hepatitis C virus (HCV). Viruses. 2019; 11(9): 850. https://doi.org/10.3390/v11090850
  102. Osman H.A., Ghweil A.A., Sabry A.M., Mahdy R.E., Khodeary A. Management of patients with hepatitis B virus reactivation post-DAA treatment of chronic hepatitis C virus infection In HCV-HBV coinfected patients with pretreatment HBeAg seroconversion and early degree of hepatic fibrosis. Infect. Drug Resist. 2019; 12: 3067–73. https://doi.org/10.2147/IDR.S215974
  103. Liu C.J., Sheen I.S., Chen C.Y., Chuang W.L., Wang H.Y., Tseng K.C., et al. Ledipasvir/Sofosbuvir for patients coinfected with chronic hepatitis C and hepatitis B in Taiwan: follow-up at 108 weeks posttreatment. Clin. Infect. Dis. 2022; 75(3): 453–9. https://doi.org/10.1093/cid/ciab971
  104. Lam L.K., Chan T.S.Y., Hwang Y.Y., Mak L.Y., Seto W.K., Kwong Y.L., et al. Hepatitis B virus reactivation in seronegative occult hepatitis B patient receiving ibrutinib therapy. Virol. J. 2023; 20(1): 168. https://doi.org/10.1186/s12985-023-02140-w
  105. Toka B., Köksal A.Ş., Dertli R., Şirin G., Fidan S., Ülger Y., et al. Hepatitis B reactivation in patients treated with direct-acting antivirals for hepatitis C. Dig. Dis. 2022; 40(5): 635–43. https://doi.org/10.1159/000521298
  106. Meschi S., Mizzoni K., Leoni B.D., Galli C., Garbuglia A.R., Belladonna S., et al. Occult HBV infection in patients infected by HIV or HCV: Comparison between HBV-DNA and two assays for HBsAg. Viruses. 2024; 16(3): 412. https://doi.org/10.3390/v16030412
  107. Maqsood Q., Sumrin A., Iqbal M., Younas S., Hussain N., Mahnoor M., et al. Hepatitis C virus/hepatitis B virus coinfection: Current prospectives. Antivir. Ther. 2023; 28(4): 13596535231189643. https://doi.org/10.1177/13596535231189643
  108. Colombatto P., Palmisano E., Ricco G., Cavallone D., Oliveri F., Coco B., et al. Different kinetics of HBV-DNA and HBsAg in HCV coinfected patients during DAAs therapy. J. Clin. Med. 2022; 11(5): 1406. https://doi.org/10.3390/jcm11051406
  109. Conners E.E., Panagiotakopoulos L., Hofmeister M.G., Spradling P.R., Hagan L.M., Harris A.M., et al. Screening and testing for hepatitis B virus infection: CDC recommendations – United States, 2023. MMWR Recomm. Rep. 2023; 72(1): 1–25. https://doi.org/10.15585/mmwr.rr7201a1
  110. Rodríguez-Tajes S., Miralpeix A., Costa J., López-Suñé E., Laguno M., Pocurull A., et al. Low risk of hepatitis B reactivation in patients with severe COVID-19 who receive immunosuppressive therapy. J. Viral Hepat. 2021; 28(1): 89–94. https://doi.org/10.1111/jvh.13410
  111. Mihai N., Olariu M.C., Ganea O.A., Adamescu A.I., Molagic V., Aramă Ș.S., et al. Risk of hepatitis B virus reactivation in COVID-19 patients receiving immunosuppressive treatment: a prospective study. J. Clin. Med. 2024; 13(20): 6032. https://doi.org/10.3390/jcm13206032
  112. Wu J., He J., Xu H. Global prevalence of occult HBV infection in children and adolescents: A systematic review and meta-analysis. Ann. Hepatol. 2024; 29(1): 101158. https://doi.org/10.1016/j.aohep.2023.101158
  113. Tsui J.I., French A.L., Seaberg E.C., Augenbraun M., Nowicki M., Peters M., et al. Prevalence and long-term effects of occult hepatitis B virus infection in HIV-infected women. Clin. Infect. Dis. 2007; 45(6): 736–40. https://doi.org/10.1086/520989
  114. Hwang J.P., Vierling J.M., Zelenetz A.D., Lackey S.C., Loomba R. Hepatitis B virus management to prevent reactivation after chemotherapy: a review. Support Care Cancer. 2012; 20(11): 2999–3008. https://doi.org/10.1007/s00520-012-1576-7
  115. Shouval D., Shibolet O. Immunosuppression and HBV reactivation. Semin. Liver Dis. 2013; 33(2): 167–77. https://doi.org/10.1055/s-0033-1345722
  116. Chen K.L., Chen J., Rao H.L., Guo Y., Huang H.Q., Zhang L., et al. Hepatitis B virus reactivation and hepatitis in diffuse large B-cell lymphoma patients with resolved hepatitis B receiving rituximab-containing chemotherapy: risk factors and survival. Chin. J. Cancer. 2015; 34(5): 225–34. https://doi.org/10.1186/s40880-015-0015-9
  117. Mezzacappa C., Lim J.K. Management of HBV reactivation: challenges and opportunities. Clin. Liver Dis. (Hoboken). 2024; 23(1): e0143. https://doi.org/10.1097/CLD.0000000000000143
  118. Anvari S., Tsoi K. Hepatitis B virus reactivation with immunosuppression: a hidden threat? J. Clin. Med. 2024; 13(2): 393. https://doi.org/10.3390/jcm13020393
  119. Zhu Y., Li H., Wang X., Zheng X., Huang Y., Chen J., et al. Hepatitis B virus reactivation increased the risk of developing hepatic failure and mortality in cirrhosis with acute exacerbation. Front. Microbiol. 2022; 13: 910549. https://doi.org/10.3389/fmicb.2022.910549
  120. Papatheodoridis G.V., Lekakis V., Voulgaris T., Lampertico P., Berg T., Chan H.L.Y., et al. Hepatitis B virus reactivation associated with new classes of immunosuppressants and immunomodulators: A systematic review, meta-analysis, and expert opinion. J. Hepatol. 2022; 77(6): 1670–89. https://doi.org/10.1016/j.jhep.2022.07.003
  121. Savaliya B.P., Shekouhi R., Mubarak F., Manaise H.K., Jimenez P.B., Kowkabany G., et al. Risk of hepatitis B virus reactivation in cancer patients undergoing treatment with tyrosine kinase-inhibitors. World J. Gastroenterol. 2024; 30(24): 3052–8. https://doi.org/10.3748/wjg.v30.i24.3052
  122. Ma H., Yan Q.Z., Ma J.R., Li D.F., Yang J.L. Overview of the immunological mechanisms in hepatitis B virus reactivation: Implications for disease progression and management strategies. World J. Gastroenterol. 2024; 30(10): 1295–312. https://doi.org/10.3748/wjg.v30.i10.1295

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Schematic representation of the hepatitis B virus structure. a – the Dane particle – the HBV virion; b – the viral genome.

Download (544KB)
Indexing metadata
3. Fig. 2. Schematic diagram of the hepatitis B virus life cycle in an infected cell. Explanations in the text.

Download (481KB)
Indexing metadata
4. Fig. 3. Changes in the levels of hepatitis B serological markers in the dynamics of HBV infection. Explanations in the text.

Download (403KB)
Indexing metadata

Copyright (c) 2025 Kushch A.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Согласие на обработку персональных данных с помощью сервиса «Яндекс.Метрика»

1. Я (далее – «Пользователь» или «Субъект персональных данных»), осуществляя использование сайта https://journals.rcsi.science/ (далее – «Сайт»), подтверждая свою полную дееспособность даю согласие на обработку персональных данных с использованием средств автоматизации Оператору - федеральному государственному бюджетному учреждению «Российский центр научной информации» (РЦНИ), далее – «Оператор», расположенному по адресу: 119991, г. Москва, Ленинский просп., д.32А, со следующими условиями.

2. Категории обрабатываемых данных: файлы «cookies» (куки-файлы). Файлы «cookie» – это небольшой текстовый файл, который веб-сервер может хранить в браузере Пользователя. Данные файлы веб-сервер загружает на устройство Пользователя при посещении им Сайта. При каждом следующем посещении Пользователем Сайта «cookie» файлы отправляются на Сайт Оператора. Данные файлы позволяют Сайту распознавать устройство Пользователя. Содержимое такого файла может как относиться, так и не относиться к персональным данным, в зависимости от того, содержит ли такой файл персональные данные или содержит обезличенные технические данные.

3. Цель обработки персональных данных: анализ пользовательской активности с помощью сервиса «Яндекс.Метрика».

4. Категории субъектов персональных данных: все Пользователи Сайта, которые дали согласие на обработку файлов «cookie».

5. Способы обработки: сбор, запись, систематизация, накопление, хранение, уточнение (обновление, изменение), извлечение, использование, передача (доступ, предоставление), блокирование, удаление, уничтожение персональных данных.

6. Срок обработки и хранения: до получения от Субъекта персональных данных требования о прекращении обработки/отзыва согласия.

7. Способ отзыва: заявление об отзыве в письменном виде путём его направления на адрес электронной почты Оператора: info@rcsi.science или путем письменного обращения по юридическому адресу: 119991, г. Москва, Ленинский просп., д.32А

8. Субъект персональных данных вправе запретить своему оборудованию прием этих данных или ограничить прием этих данных. При отказе от получения таких данных или при ограничении приема данных некоторые функции Сайта могут работать некорректно. Субъект персональных данных обязуется сам настроить свое оборудование таким способом, чтобы оно обеспечивало адекватный его желаниям режим работы и уровень защиты данных файлов «cookie», Оператор не предоставляет технологических и правовых консультаций на темы подобного характера.

9. Порядок уничтожения персональных данных при достижении цели их обработки или при наступлении иных законных оснований определяется Оператором в соответствии с законодательством Российской Федерации.

10. Я согласен/согласна квалифицировать в качестве своей простой электронной подписи под настоящим Согласием и под Политикой обработки персональных данных выполнение мною следующего действия на сайте: https://journals.rcsi.science/ нажатие мною на интерфейсе с текстом: «Сайт использует сервис «Яндекс.Метрика» (который использует файлы «cookie») на элемент с текстом «Принять и продолжить».